Source:http://linkedlifedata.com/resource/pubmed/id/12856919
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2003-7-14
|
pubmed:abstractText |
A series of 2',3'-dideoxy (D2) and 2',3'-didehydro-2',3'-dideoxy (D4) 5-fluorocytosine nucleosides modified with substituted benzoyl, heteroaromatic carbonyl, cycloalkylcarbonyl and alkanoyl at the N4-position were synthesized and evaluated for anti-human immunodeficiency virus type 1 (HIV-1) and anti-hepatitis B virus (HBV) activity in vitro. For most D2-nucleosides, N4-substitutions improved the anti-HIV-1 activity markedly without increasing the cytotoxicity. In the D4-nucleosides series, some of the substituents at the N4-position enhanced the anti-HIV-1 activity with a modest increase in the cytotoxicity. The most potent and selective N4-modified nucleoside for the D2-series was N4-p-iodobenzoyl-D2FC, which had a 46-fold increase in anti-HIV-1 potency in MT-2 cells compared to the parent nucleoside D-D2FC. In the D4-series, N4-p-bromobenzoyl-D4FC was 12-fold more potent in MT-2 cells compared to the parent nucleoside D-D4FC. All eight N4-p-halobenzoyl-substituted D2- and D4-nucleosides evaluated against HBV in HepAD38 cells demonstrated equal or greater potency than the two parental compounds, D-D2FC and D-D4FC. The N4-modification especially in the D2-nucleoside series containing the N4-nicotinoyl, o-nitrobenzoyl and n-butyryl showed a significant reduction in mitochondrial toxicity relative to the parent nucleoside analogue. Although the 5'-triphosphate of the parent compound (D-D4FC-TP) was formed from the N4-acyl-D4FC analogues in different cells, the levels of the 5'-triphosphate nucleotide did not correlate with the cell-derived 90% effective antiviral concentrations (EC90), suggesting that a direct interaction of the triphosphates of these N4-acyl nucleosides was involved in the antiviral activity.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0956-3202
|
pubmed:author |
pubmed-author:AdamsMarjorieM,
pubmed-author:Erickson-ViitanenSusanS,
pubmed-author:GallagherKarenK,
pubmed-author:GeleziunasRomasR,
pubmed-author:GrierJason PJP,
pubmed-author:MathewJudy SJS,
pubmed-author:OttoMichael JMJ,
pubmed-author:PaiS BalakrishnaSB,
pubmed-author:RachakondaSugunaS,
pubmed-author:SchinaziRaymond FRF,
pubmed-author:ShiGuoenG,
pubmed-author:ShiJunxingJ,
pubmed-author:StuyverLievenL,
pubmed-author:TharnishPhillip MPM,
pubmed-author:WatanabeKyoichi AKA,
pubmed-author:WuJing-TaoJT,
pubmed-author:ZhangHangchunH
|
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
81-90
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:12856919-Animals,
pubmed-meshheading:12856919-Anti-HIV Agents,
pubmed-meshheading:12856919-Antiviral Agents,
pubmed-meshheading:12856919-Cell Division,
pubmed-meshheading:12856919-Cell Line,
pubmed-meshheading:12856919-Cell Line, Tumor,
pubmed-meshheading:12856919-Cercopithecus aethiops,
pubmed-meshheading:12856919-Dose-Response Relationship, Drug,
pubmed-meshheading:12856919-HIV-1,
pubmed-meshheading:12856919-Hepatitis B virus,
pubmed-meshheading:12856919-Humans,
pubmed-meshheading:12856919-Inhibitory Concentration 50,
pubmed-meshheading:12856919-Models, Chemical,
pubmed-meshheading:12856919-Vero Cells,
pubmed-meshheading:12856919-Zalcitabine
|
pubmed:year |
2003
|
pubmed:articleTitle |
N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity.
|
pubmed:affiliation |
Pharmasset, Inc., Tucker, Ga., USA. jshi@pharmasset.com
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|